WeVote
Log In

Bill

Bill

SB 1495

Opioids - As introduced, adds Alvogen, Inc., Apotex Corp., and Zydus Pharmaceuticals (USA) Inc. to the list of companies that may be released by the attorney general for pending or future claims regarding opioids. - Amends TCA Title 20 and Title 33.

114th Regular Session (2025-2026) Introduced by Ferrell Haile

Tennessee authorizes AG to release three pharmaceutical companies from opioid-related litigation claims in exchange for settlement terms not detailed in the bill.

Transmitted to Governor for action.
#opioids
0
WeVote Research Nonpartisan
Bill Summary · SB 1495

Legislative bill overview

SB 1495 authorizes Tennessee's attorney general to release three pharmaceutical companies—Alvogen, Inc., Apotex Corp., and Zydus Pharmaceuticals (USA) Inc.—from pending or future legal claims related to opioid litigation. The bill modifies Tennessee Code Annotated Titles 20 and 33 to add these companies to an existing list of entities eligible for claim releases.

Why is this important

This bill directly affects Tennessee's ability to pursue or settle opioid-related lawsuits against specific manufacturers. Given the nationwide opioid crisis and resulting litigation against pharmaceutical companies, decisions to release companies from claims have significant consequences for state recovery efforts and public accountability. The bill's passage suggests settlement negotiations or legal resolutions may already be underway with these three companies.

Potential points of contention

  • Settlement transparency: The bill provides limited public information about what compensation or concessions Tennessee may receive in exchange for releasing these companies from claims
  • Scope of immunity: Releasing companies from "pending or future claims" creates broad legal protection that may limit Tennessee's legal recourse if new evidence or harms emerge
  • Pharmaceutical accountability: Adding more companies to the release list may be viewed as reducing corporate accountability for opioid marketing and distribution practices

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.